A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022008790
Abstract: Key Points • Patients with DLBCL Richter transformation of CLL have a poor prognosis, especially if they have had prior BTKi exposure.• Nivolumab and ibrutinib combination therapy is a safe and potential treatment option in… read more here.
Keywords: richter transformation; study nivolumab; phase study; transformation cll ... See more keywords